MLTX — MoonLake Immunotherapeutics Share Price
0.000.00%
Last trade - 00:00- $2.47bn
- $1.93bn
- 39
- 33
- 52
- 36
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.55 | ||
| Price to Tang. Book | 4.55 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -10.99% | ||
| Return on Equity | -13.92% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- August 13th, 2020
- Public Since
- October 20th, 2020
- No. of Shareholders
- 9
- No. of Employees
- 50
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 63,869,904
- Address
- Dorfstrasse 29, ZUG, 6300
- Web
- https://moonlaketx.com/
- Phone
- +41 415108022
- Contact
- Atif Khan
- Auditors
- BAKER TILLY US LLP
Upcoming Events for MLTX
MoonLake Immunotherapeutics at Goldman Sachs Global Healthcare Conference
MoonLake Immunotherapeutics at Stifel European Healthcare Summit
Q2 2024 MoonLake Immunotherapeutics Earnings Release
Q3 2024 MoonLake Immunotherapeutics Earnings Release
Similar to MLTX
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the MoonLake Immunotherapeutics share price?
As of Today at 16:49 UTC, shares in MoonLake Immunotherapeutics are trading at $38.66. This share price information is delayed by 15 minutes.
How has the MoonLake Immunotherapeutics share price performed this year?
Shares in MoonLake Immunotherapeutics last closed at $38.66 and the price had moved by +40.33% over the past 365 days. In terms of relative price strength the MoonLake Immunotherapeutics share price has outperformed the S&P500 Index by +10.84% over the past year.
What are the analyst and broker recommendations for MoonLake Immunotherapeutics?
The overall consensus recommendation for MoonLake Immunotherapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the MoonLake Immunotherapeutics dividend yield?
MoonLake Immunotherapeutics does not currently pay a dividend.
Does MoonLake Immunotherapeutics pay a dividend?
MoonLake Immunotherapeutics does not currently pay a dividend.
When does MoonLake Immunotherapeutics next pay dividends?
MoonLake Immunotherapeutics does not currently pay a dividend.
How do I buy MoonLake Immunotherapeutics shares?
To buy shares in MoonLake Immunotherapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of MoonLake Immunotherapeutics?
As of the previous close price of $38.66, shares in MoonLake Immunotherapeutics had a market capitalisation of $2.47bn.
Where are MoonLake Immunotherapeutics shares listed?
Here are the trading details for MoonLake Immunotherapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: MLTX
What kind of share is MoonLake Immunotherapeutics?
Based on an overall assessment of its quality, value and momentum MoonLake Immunotherapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a MoonLake Immunotherapeutics share price forecast for 2024?
The analyst consensus target price for shares in MoonLake Immunotherapeutics is $70.93. That is 83.47% above the last closing price of $38.66.
Analysts covering MoonLake Immunotherapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.26 for the next financial year.
What is the trend in the MoonLake Immunotherapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like MoonLake Immunotherapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -26.71%.
As of the last closing price of $38.66, shares in MoonLake Immunotherapeutics were trading -25.13% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the MoonLake Immunotherapeutics PE Ratio?
The MoonLake Immunotherapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $38.66.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of MoonLake Immunotherapeutics?
We do not have data on MoonLake Immunotherapeutics' directors